Sanofi-Aventis CEO Plans Focus Switch From West To China
This article was originally published in PharmAsia News
Executive Summary
France's Sanofi-Aventis told reporters it plans to take advantage of China's massive health-reform plan by expanding its Chinese business. To do so, Sanofi-Aventis is switching its emphasis away from reliance on blockbuster drugs in the developed world. The firm's CEO Christopher Viehbacher told reporters he will not be satisfied with just operating on the margins of China's healthcare system. Viehbacher said the company is looking for acquisitions, joint ventures or equity stakes with Chinese drug makers to give the company a large presence in basic drugs. (Click here for more - a subscription may be required